A contraindication to the use of GLP-1 RA (i.e., treatment discontinuation) in patients with depression or suicidal ideation could be another explanation, but this could only be confirmed if the same effects were not found in the negative control group using DPP-4 inhibitors, which is not the case here. The gene discussed is GLP1R; the disease is depressive disorder.